OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacology & Therapeutics is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial Board	425
Adenosine receptor signalling as a driver of pulmonary fibrosis	413
Inflammation, lipids, and pain in vulvar disease	348
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	281
Matrikines in the skin: Origin, effects, and therapeutic potential	271
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	233
Collateral lethality: A unique type of synthetic lethality in cancers	211
Treatment approaches for alcohol use disorder with metabolic dysfunction	199
SGLT2 inhibitors: Do they have antiarrhythmic properties?	187
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	165
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	151
The role of macrophages in asthma-related fibrosis and remodelling	122
Non-canonical G protein signaling	119
Endothelial dysfunction as a complication of anti-cancer therapy	117
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	114
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	110
Potential neonatal toxicity of new psychoactive substances	110
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	110
Treatment strategies for leptomeningeal disease in patients with breast cancer	108
Unfolded protein responses: Dynamic machinery in wound healing	107
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	106
TAAR1 as an emerging target for the treatment of psychiatric disorders	105
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	103
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	99
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	94

Management of drug-resistant hypertension as a heterogeneous disorder	88
Boron in cancer therapeutics: An overview	86
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	86
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	85
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	85
Editorial Board	84
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	82
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	82
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	81
Dysregulation of metabolic pathways in pulmonary fibrosis	80
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	78
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	78
Editorial Board	76
Editorial Board	74
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	74
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	73
PGRMC1: An enigmatic heme-binding protein	73
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	73
Bispecific antibodies for the treatment of neuroblastoma	72
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	71
Review: Sex-related differences in the treatment of cardiac arrhythmia	70
Pharmacological treatment of cardiogenic shock – A state of the art review	70
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	68
Natural products that alleviate depression: The putative role of autophagy	68
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	67
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	67
DNA methylation in cell plasticity and malignant transformation in liver diseases	66
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	66
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	66
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	65
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	63
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	62
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	61
Insights into effective protocol structuring: optimizing dosing strategies, experimental design, and statistical approaches	61
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	61
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	60
Stabilizing the neural barrier – A novel approach in pain therapy	60
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	60
Advances in pathogenesis and therapeutic strategies for osteoporosis	60
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	60
Regulation of feeding and therapeutic application of bioactive peptides	60
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	59
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	58
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	58
Drug-induced Torsades de pointes: Insights from a canine model of chronic atrioventricular block	56
The role of drug-metabolizing enzymes in synthetic lethality of cancer	55
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	55
Optimizing drug therapies in cardiac amyloidosis	54
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	53

Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	53
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	52
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	52
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	52
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	51
Therapeutic targeting of DNA methylation alterations in cancer	50
Editorial Board	49
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	49
Corrigendum to “Drug discovery through biophysical techniques: Methods and applications” [pharmacology and therapeutics volume 277 (2026) 108947]	49
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	48
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	48
Pharmacological potential of cyclic nucleotide signaling in immunity	48
Organic anion transporters in remote sensing and organ crosstalk	48
MicroRNAs in drug addiction: Current status and future perspectives	48
CDNF and ER stress: Pharmacology and therapeutic possibilities	48
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	48
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	47
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	47
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	47
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	47
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	47
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	46
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	46
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	46
Editorial Board	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	44
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	44
Exploring the landscape of post-translational modification in drug discovery	44
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	44
The role and participation of immune cells in the endometrial tumor microenvironment	44
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	43
Molecular mechanisms of ferroptosis and their involvement in brain diseases	43
G protein-coupled estrogen receptor biased signaling in health and disease	43
Oxidative stress and antioxidant therapeutic mechanisms	43
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	43
Editorial Board	42
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation	42
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	41
RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma	41
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	41
Platelet lipid metabolism in vascular thrombo-inflammation	41
Potential targeting of the tumor microenvironment to improve cancer virotherapy	40
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	40
Targeting cell cycle checkpoints for glioma therapy	40
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	40
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	39
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	37
Prolactin and pain of endometriosis	37
Understanding the molecular bridges between the drugs and immune cell	37
Editorial Board	37
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	36
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	36
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	36
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	36
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	36
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	36
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	35
Plant-derived nanovesicles and therapeutic application	35
Early life adversities, psychopathologies and novel pharmacological strategies	35
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	35
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	35
From bench to clinic: Emerging therapies for corneal scarring	35
Gene and stem cell therapy for inherited cardiac arrhythmias	34
Biased signaling in drug discovery and precision medicine	34
The antidepressant actions of ketamine and its enantiomers	34
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	34
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	34
Editorial Board	34
Editorial Board	34
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	34
Retina-directed gene therapy: Achievements and remaining challenges	33
Anti-cancer activity of sustained release capsaicin formulations	33
Bile acids and neurological disease	33
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	33
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	33
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	33
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	33